Genetics, Genomics & Molecular Diagnostics News

The agency expects existing programs to guide its regulation, adding that modified portions of animal genomes would be considered drugs.

Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.

The two new single-cell RNA-sequencing methods aim to overcome some of the limitations of single-cell transcriptomics.

Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.

The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.

The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.

The firm has asked the SEC to withdraw a registration statement for a previously planned $8 million equity financing, saying it no longer needs the financing.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Humanized NSG and NSG-SGM3 mice are a new preclinical bridge for immune-oncology therapies. Humanized mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.

Genotoxicity workflows performed manually are subject to workflow bottlenecks, where the throughput is inherently limited, and active time spent performing the tests reduces the lab’s overall efficiency. Additionally, variability associated with operator technique and laboratory conditions could lead to a loss in precision, or worse, systematic errors that can skew results. This article demonstrates automated imaging as it pertains to the comet and gamma-H2AX assays in order to simplify genotoxicity assay workflows and provide robust results.

Stringent guidelines of quality assurance and control (QA/QC) serve as the foundation for dependable and reproducible results in any analytical endeavor. Here we highlight step-by-step, the measures implemented by Myriad RBM that take Luminex xMAP technology to a high level of reproducibility and ruggedness. The Myriad RBM platform combines the sensitivity and dynamic range of microsphere-based immuno-multiplexing with the precision and dependability of automated liquid handling.